Nutriband Inc. — Form 10-Q Summary
Reporting period: Three months ended April 30, 2024 (the company’s first fiscal quarter of 2025; fiscal year ends January 31). Results are unaudited. Nutriband develops transdermal pharmaceutical products, led by its AVERSA abuse-deterrent fentanyl system, and also earns revenue from contract manufacturing and related services.
Financial performance and condition
| Metric | Q1 ended Apr. 30, 2024 | Comparable 2023 period |
|---|---|---|
| Revenue | $408,532 | $476,932 |
| Gross profit / gross margin | $164,786 / 40.3% | $222,284 / 46.6% |
| Research and development | $974,535 | $400,430 |
| Selling, general and administrative | $1,079,728 | $839,732 |
| Operating loss | $(1,889,477) | $(1,017,878) |
| Net loss / loss per share | $(1,898,077) / $(0.21) | $(1,015,229) / $(0.13) |
| Cash used in operating activities | $(833,926) | $(749,864) |
Cash and cash equivalents were $8,347,740 at April 30, versus $492,942 at January 31. Working capital was $7,313,082, compared with $22,870. Cash provided by financing was $8,694,919, principally from an $8.4 million equity financing and $300,000 of related-party credit-line advances; investing activities used $6,195. The balance sheet reported total liabilities of $1,791,367, including approximately $501,928 of notes payable. Cash substantially exceeded reported notes payable. Current assets were $8,729,940 and current liabilities were $1,416,858.
Total assets were $15,154,480, including $5,021,713 of goodwill. The company reported stockholders’ equity of $13,363,113 and an accumulated deficit of $29,878,096. The quarter’s $422,955 of employee option compensation was non-cash.
Material changes and financing
- Revenue declined about 14% year over year. All quarterly revenue was from sales of goods, principally Pocono Pharmaceuticals; 2023 included $75,875 of 4P Therapeutics services revenue. The company said its prior 4P customer contract had ended and 4P focused primarily on AVERSA development.
- Gross margin fell to 40.3% from 46.6%. R&D expense more than doubled, mainly reflecting AVERSA development costs, including work with Kindeva; SG&A also increased.
- On April 19, the company raised $8.4 million by issuing 2.1 million units at $4 each. Each unit included one common share and warrants for two additional shares at $6.43, expiring in 2029. Related parties invested $7.12 million. The financing added 4.2 million warrants, creating potential dilution.
- At April 30, the company had 10,959,870 common shares outstanding; it reported 11,036,100 outstanding as of May 31. A subsequent May 14 conversion of $300,000 of related-party debt plus accrued interest issued 76,230 shares; a May 22 amendment provided warrants for an additional 152,460 shares at $6.43.
Outlook, risks and unusual items
- Management said the $8.35 million cash balance and financing support its estimate that funds will be sufficient for at least one year, and that substantial doubt about continuing as a going concern is alleviated. The company nevertheless has a history of operating losses and negative operating cash flow and relies on capital raising and debt.
- The company estimated approximately $13 million would be required for AVERSA fentanyl development, clinical manufacturing and trials, while warning total costs could be materially higher. A January 2024 Kindeva agreement covers commercial manufacturing-process development and clinical supplies; estimated completion cost is about $8.1 million, and the company cited an expected FDA submission in 12–18 months. The required FDA approval is not assured.
- The company identified ongoing risks from clinical and regulatory delays or costs, inability to obtain approval or commercialize products, competition, need for additional financing, and potential dilution. Its forecast of increased demand for transdermal patches was not quantified.
- A lawsuit by Joseph Gunnar and Lucosky Brookman alleges breach of contract and other claims after termination of an engagement letter. Gunnar seeks more than $500,000 plus punitive damages, and Lucosky Brookman seeks legal fees. Nutriband denies the allegations and asserts counterclaims seeking $1 million for each of two claims; discovery was ongoing. The filing does not provide a clear estimate of potential loss.
- Disclosure controls were assessed as ineffective. Management cited material weaknesses involving segregation of duties, qualified accounting personnel and prior reliance on outside consultants, while describing remediation efforts.
- Cash of $7,879,000 exceeded federally insured limits. The company also remains contingently responsible for repayment shortfalls related to a $106,528 advance against a bankruptcy claim; the underlying receivable was fully reserved.
Most important facts for investors to verify
- Whether AVERSA development, clinical testing and the expected FDA submission remain on schedule and within available funding.
- Cash burn, remaining availability under the $5 million related-party credit facility, and dependence on related-party funding.
- The actual and potential dilution from the April financing, outstanding warrants and options, and the subsequent debt conversion.
- The status and potential financial exposure of the Gunnar/Lucosky Brookman litigation and the bankruptcy-claim repayment obligation.
- Several filing figures conflict: the financial statements report 2024 SG&A of $1,079,728 and 2023 revenue of $476,932, while MD&A contains different values; MD&A also gives a different 2023 net loss. Confirm the controlling figures against the filed financial statements and XBRL data.